SixPeaks Bio

SixPeaks Bio is a private, pre-clinical-stage biotech focused on addressing a critical unmet need in the booming obesity therapeutics market: the loss of lean muscle mass associated with GLP-1-based weight loss drugs. The company's lead program targets ActRIIA/B (Activin Receptor Type IIA/B) to protect and potentially build muscle, positioning it as a potential combination therapy. Backed by a $110 million Series A financing and led by a team with deep experience in obesity drug development from major pharma, SixPeaks is leveraging its antibody and conjugate platform to build a pipeline of next-generation cardiometabolic therapies.

State-of-the-art antibody engineering and conjugation platform for developing monoclonal antibodies, bispecifics, and precision medicine conjugates (e.g., antibody-peptide fusions) with a focus on multi-pharmacology.

SixPeaks operates in a nascent but increasingly competitive space focused on muscle health in obesity. It faces potential competition from other biotechs targeting myostatin/ActRII pathways (e.g., scholars developing next-gen molecules) and from large pharmaceutical companies that may develop in-house combination therapies for their own GLP-1 assets.